Sanofi has announced the launch of Verorab in the UK, an inactivated rabies vaccine indicated for pre-exposure and post-exposure prophylaxis of rabies in all age groups. This launch is based on extensive clinical data from over 13,000 individuals. Sanofi Inactivated Rabies Vaccine has been approved and widely used in more than 80 countries. It is estimated that between 41M-70M individuals have received the vaccine since its first licensure in May 1985, in France.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi to resolve roughly 5,000 Zantac lawsuits in U.S., Bloomberg says
- Dr. Reddy’s enters partnership with Sanofi to distribute vaccines in India
- AstraZeneca, Sanofi announce Beyfortus approved in Japan
- Annexon price target raised to $12 from $11 at Wells Fargo
- Sanofi’s Amlitelimab Shows Lasting Benefits
